Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P51797
UPID:
CLCN6_HUMAN
Alternative names:
Chloride channel protein 6; Chloride transport protein 6
Alternative UPACC:
P51797; A8K1T4; B4DGT7; F8W9R3; O60818; O60819; O60820; O60821; P78520; P78521; Q17R81; Q5SNW2; Q5SNW3; Q5SNX1; Q5SNX2; Q5SNX3; Q99427; Q99428; Q99429
Background:
H(+)/Cl(-) exchange transporter 6, also known as Chloride channel protein 6 or Chloride transport protein 6, plays a crucial role in cellular processes by mediating the exchange of chloride ions against protons. This action contributes significantly to the acidification of the late endosome lumen, a process vital for cellular homeostasis. The protein is a member of the CLC channel family, which includes both chloride channels and proton-coupled anion transporters.
Therapeutic significance:
The protein is implicated in a severe neurodegenerative disorder, characterized by developmental delay, respiratory insufficiency, and brain abnormalities. Understanding the role of H(+)/Cl(-) exchange transporter 6 could open doors to potential therapeutic strategies for this debilitating condition.